Coronary artery stenting in patients with coronary heart diseaseand cancer

Authors: Nikitina T.G.1, Dombrovskiy M.M.1, Alekyan B.G.2, Davydov M.I..3, Bockeria L.A.1

Company: 1 A.N. Bakoulev Scientific Center for Cardiovascular Surgery of Ministry of Health of the Russian Federation; Rublevskoe shosse, 135, Moscow, 121552, Russian Federation;
2 A.V. Vishnevsky Institute of Surgery of Ministry of Health of the Russian Federation; Bol'shaya Serpukhovskaya ulitsa, 27, Moscow, 115478, Russian Federation;
3 N.N. Blokhin Russian Oncological Scientific Center of Ministry of Health of the Russian Federation; Kashirskoe shosse, 23, Moscow, 115478, Russian Federation

For correspondence:  Sign in or register.


DOI: https://doi.org/10.15275/kreatkard.2016.04.04

For citation: Nikitina T.G., Dombrovskiy M.M., Alekyan B.G., Davydov M.I., Bockeria L.A. Coronary artery stenting in patients with coronary heart diseaseand cancer. Creative Cardiology. 2016; 10 (4): 296-305.(in Russ.).

Keywords: percutaneous coronary intervention oncopathology coronary heart disease staged treatment

Full text:  

 

Abstract

Objective. Analysis of the immediate and long-term results of percutaneous coronary intervention in patients with coronary heart disease (CHD) and oncopathology.
Material and methods. This paper presents the results of a two-stage treatment of 41 patients (35 men and 6 women) with CHD and oncopathology. The mean age was 67.6±6.4 years. The first step was performed percutaneous coronary intervention (PCI), and the second – the treatment of cancer pathology (20 patients underwent surgical treatment, 18 – chemotherapy or radiation therapy, and 3 – combined treatment).
Results. There were no cases of intraoperative and hospital mortality during the two-stage treatment of coronary heart disease and cancer pathology. Over the entire period of observation a death due to acute coronary syndrome was not registered. One case of Q-wave myocardial infarction was registered in a patient in 3 years after myocardial revascularization (she died in 4 months after myocardial infarction due to progression of cancer). The mortality rate for five years of follow-up was 22%: 5 (12.2%) patients died from cancer pathology at the first year after PCI, 4 (9.8%) patients died of cancer pathology in 1.5, 2, 3.5 and 4.5 years after percutaneous revascularization. The majority (96.9%) of patients had received good indicators of quality of life in the long term period of observation.
Conclusion. Percutaneous coronary intervention - an effective and safe method for myocardial revascularization in patients with coronary artery disease and oncopathology. The use of endovascular myocardial revascularization in the first stage of cancer patients reduces the risk of cardiovascular complications during the treatment of cancer (surgery, chemotherapy, radiation therapy).

References

  1. Mistiaen W.P. Cancer in heart disease patients: what are the limitations in the treatment strategy? Fut. Cardiol. 2013; 9 (4): 535–47.
  2. Krone R.J. Managing coronary artery disease in the cancer patient. Prog. Cardiovasc. Dis. 2010; 53 (2): 149–56.
  3. Kristensen S.D., Knuuti J., Saraste A., Anker S., Bøtker H.E., De Hert S. et al. 2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). Eur. Heart J. 2014; 35 (35): 2383–431.
  4. Fujikawa T., Tanaka A. Successful multidisciplinary treatment of hilar cholangiocarcinoma in a patient with complicated new-onset coronary artery disease. BMJ Case Rep. 2014. DOI: 10.1136/bcr-2014-203941.
  5. Fukuyama K., Fujikawa T., Kuramitsu S., Tanaka A. Successful treatment of bleeding large duodenal gastrointestinal stromal tumour in a patient under dual antiplatelet therapy after recent drugeluting coronary stent implantation. BMJ Case Rep. 2014. DOI: 10.1136/bcr-2014-204462.
  6. Savonitto S., D'Urbano M., Caracciolo M., Barlocco F., Mariani G., Nichelatti M. et al. Urgent surgery in patients with a recently implanted coronary drug-eluting stent: a phase II study of “bridging” antiplatelet therapy with tirofiban during temporary withdrawal of clopidogrel. Br. J. Anaesth. 2010; 104 (3): 285–91.
  7. Warshauer J., Patel V.G., Christopoulos G., Kotsia A.P., Banerjee S., Brilakis E.S. Outcomes of preoperative bridging therapy for patients undergoing surgery after coronary stent implantation: a weighted meta-analysis of 280 patients from eight studies. Cathet. Cardiovasc. Interv. 2015; 85 (1): 25–31.
  8. Guo Q., Zhang B., Dong X., Xie Q., Guo E., Huang H. et. al. Elevated levels of plasma fibrinogen in patients with pancreatic cancer: possible role of adistant metastasis predictor. Pancreas. 2009; 38 (3): e75–9.
  9. Lee S.E., Lee J.H., Ryu K.W., Nam B.H., Cho S.J., Lee J.Y. et al. Preoperative plasma fibrinogen level is a useful predictor ofadjacent organ involvement in patients with advanced gastric cancer. J. Gastric. Cancer. 2012; 12 (2): 81-7.
  10. Ishikawa S., Kasai Y., Matsuura N., Tarumi S., Nakano J., Okuda M. et al. Perioperative management of lung cancer patients under antiplatelet or anticoagulant therapy. Kyobu Geka. 2015; 68 (4): 262–5.
  11. Maki M., Tsubochi H., Endo T., Endo S. Management of patients with ischemic heart disease in lung cancer resection. Kyobu Geka. 2015; 68 (4): 271–7.
  12. Zhang H., Wang D.X., Xiao F., Li J., He Z.S., Wan Y.L. The impact of previous or concomitant myocardium revascularization on the outcomes of patients undergoing major non-cardiac surgery. Interact. Cardiovasc. Thorac. Surg. 2009; 9 (5): 788–92.
  13. Ciriaco P., Carretta A., Calori G., Mazzone P., Zannini P. Lung resection for cancer in patients with coronary arterial disease: analysis of shortterm results. Eur. J. Cardiothorac. Surg. 2002; 22 (1): 35–40.
  14. Voltolini L., Rapicetta C., Luzzi L., Paladini P., Ghiribelli C., Scolletta S. et al. Lung resection for non-small cell lung cancer after prophylactic coronary angioplasty and stenting: short- and long-term results. Minerva Chir. 2012; 67 (1): 77–85.
  15. Shestopalova I.M. Diagnostic strategy and treatment of coronary heart disease in the thoraco-abdominal cancersurgery. Abstract of the thesis of MD. Moscow; 2010 (in Russ.).
  16. Davydov M.I., Аkchurin R.S., Gerasimov S.S., Dzemeshkevich S.L., Brand Ya.B., Dolgov I.M. et al. Combined surgical treatment of cancer patients with competing cardiovascular disease when the tumor lesions of the lungs and mediastinum. Khirurgiya. 2010; 8: 4–11 (in Russ.).

Chief Editor

Leo A. Bockeria, MD, PhD, DSc, Professor, Academician of Russian Academy of Sciences, President of Bakoulev National Medical Research Center for Cardiovascular Surgery